TRVI
Trevi Therapeutics Inc

1,799
Mkt Cap
$1.36B
Volume
2.3M
52W High
$14.39
52W Low
$4.85
PE Ratio
-33.07
TRVI Fundamentals
Price
$10.61
Prev Close
$10.70
Open
$10.74
50D MA
$11.16
Beta
0.61
Avg. Volume
1.28M
EPS (Annual)
-$0.3173
P/B
7.43
Rev/Employee
$0.00
$1,499.53
Loading...
Loading...
News
all
press releases
Research Analysts Issue Forecasts for TRVI FY2026 Earnings
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 earnings estimates for Trevi Therapeutics in a research note issued on Wednesday, March 18th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.54) per sha...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Given New $24.00 Price Target at JonesTrading
JonesTrading reduced their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a report on Thursday...
MarketBeat·3d ago
News Placeholder
What is HC Wainwright's Forecast for TRVI Q1 Earnings?
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Trevi Therapeutics in a note issued to investors on Wednesday, March 18th. HC Wainwright analyst B. Folkes expects that the company will earn ($0.08) per share...
MarketBeat·4d ago
News Placeholder
Trevi Therapeutics Q4 Earnings Call Highlights
Trevi Therapeutics (NASDAQ:TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a pivotal year driven by positive clinical data...
MarketBeat·4d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Given New $18.00 Price Target at Morgan Stanley
Morgan Stanley reduced their price target on Trevi Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Wednesday...
MarketBeat·4d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Better-Than-Expected Earnings
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Earnings Beat...
MarketBeat·4d ago
News Placeholder
Trevi Therapeutics (TRVI) Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·4d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from D. Boral Capital
D. Boral Capital reiterated a "buy" rating and set a $19.00 price target on shares of Trevi Therapeutics in a research note on Wednesday...
MarketBeat·4d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $24.00
Needham & Company LLC boosted their price target on Trevi Therapeutics from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Wednesday...
MarketBeat·4d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Releases Earnings Results, Beats Estimates By $0.04 EPS
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04...
MarketBeat·5d ago
<
1
2
...
>

Latest TRVI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.